Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers (STRIDE 2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01849965
Recruitment Status : Terminated
First Posted : May 9, 2013
Last Update Posted : December 12, 2017
Sponsor:
Collaborator:
Integrium
Information provided by (Responsible Party):
Integra LifeSciences Corporation

Brief Summary:
To determine if aclerastide (DSC127) is effective in increasing incidence of complete wound closure up to 10 weeks confirmed 2 weeks later, compared with vehicle (gel without active ingredient) and compared with a standard-of-care gel, in subjects with diabetes mellitus (DM) who have chronic Wagner Grade 1 or 2 diabetic foot ulcers, 0.75 - 6cm2 in size.

Condition or disease Intervention/treatment Phase
Diabetic Foot Ulcers Drug: DSC127 Drug: placebo vehicle gel Drug: Standard of Care gel, Aquasite Phase 3

Detailed Description:

Subjects will undergo a two week screening period to assess plantar ulcer healing, and those healing less than 30% will be eligible for randomization providing all other criteria are met. Four weeks of "blinded" randomized treatment follows the screening period, and an observation period of six weeks follows the treatment period. If the ulcer closes during the treatment or observation period, the closure will be confirmed at a visit two weeks later, and at this time the subjects enters a durability assessment period of up to 12 weeks.

All aspects of Standard of Care are followed throughout the study period.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 396 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Parallel-group, Vehicle and Standard of Care-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus
Study Start Date : April 2013
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: DSC127
DSC127 0.03% in a vehicle gel (hydroxyethyl cellulose (HEC) with parabens)
Drug: DSC127
DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever occurs sooner.

Placebo Comparator: Vehicle gel
Vehicle gel comprising HEC with parabens
Drug: placebo vehicle gel
Placebo Comparator: Standard of Care gel
Aquasite gel, as standard of care gel
Drug: Standard of Care gel, Aquasite



Primary Outcome Measures :
  1. The proportion of subjects with a target ulcer which achieves complete wound closure by 10 weeks (confirmed 2 weeks later) after initiation of treatment. [ Time Frame: Target ulcer must achieve complete wound closure by 10 weeks post first treatment ]
    Primary endpoint of complete closure is assessed by the Principal Investigator at the site; ulcer measurements are calculated via tracings submitted to the Canfield system, and photographs are collected as confirmation of closure via the Canfield system. Assessment of aclerastide (DSC127) vs vehicle control.


Secondary Outcome Measures :
  1. The proportion of subjects with a target ulcer which achieves complete wound closure by 10 weeks (confirmed two weeks later) after initiation of treatment. [ Time Frame: Target ulcer must achieve complete wound closure by 10 weeks post first treatment ]
    Primary endpoint of complete closure is assessed by the Principle Investigator at the site; ulcer measurements are calculated via tracings submitted to the Canfield system, and photographs are collected as confirmation of closure via the Canfield system. Assessment of aclerastide (DSC127) vs Standard of Care control.


Other Outcome Measures:
  1. Time to the visit where the target ulcer achieves confirmed complete wound closure [ Time Frame: Measurements to ten weeks post first dose ]
  2. Percent reduction in target ulcer area per week. [ Time Frame: Up to ten weeks post first dose ]
  3. Incidence of and time to target ulcer recurrence after confirmed complete wound closure has been established. [ Time Frame: To a maximum of 24 weeks post first dose ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female ambulatory subject age ≥18 years at the time of informed consent
  • Has type 1 or type 2 DM under metabolic control as confirmed by a glycosylated hemoglobin (HbA1c) of ≤12% and a serum creatinine level of ≤3mg/dL
  • At Screening and Baseline (prior to randomization), subject has at least one ulcer that fulfills all of the following criteria:

    • present for ≥1 month and ≤1 year
    • Partial- or full- thickness and not involving bone, tendon, or capsule (probing to tendon or capsule), i.e. Wagner Grade 1 or 2.
    • Has no sign of infection or osteomyelitis
    • Plantar neuropathic ulcer - predominately be on the plantar surface (i.e. weight bearing) of the foot to ensure adequate off-loading and may include the toes
    • Size of the target ulcer must be 0.75-6 cm2.
    • Target ulcer must be non-healing as defined as <30% reduction in area in response to standard of care during the Screening Period

      • If more than one ulcer is present that meets the inclusion criteria, the largest one will be considered the target ulcer
      • If there are two ulcers of the same size that meet all criteria, the one with the higher Wagner Grade will be considered the target ulcer
      • If there are two ulcers of the same size and the same Wagner Grade, the one present for the longest qualifying time will be the target ulcer.
      • Non-target ulcers will also be treated according to standard of care (Acute Charcot Neuroarthropathy of the foot with the target ulcer must be excluded)
  • Has an ankle brachial index (ABI) ≥0.7 on the foot with the target ulcer.
  • Has an assessment of the baseline level of neuropathy of the foot using Semmes-Weinstein filaments.
  • A female subject of childbearing potential must have a negative serum pregnancy test at the time of Screening.
  • A female subject of childbearing potential must be willing to use a medically acceptable method of birth control, such as Essure®, hormonal contraception (oral pills, implantable device, or skin patch), intrauterine device, tubal ligation, or double barrier throughout the study. A female subject of childbearing potential who practices abstinence is not required to employ birth control.
  • Has the ability and willingness to understand and comply with study procedures and to give written informed consent prior to enrollment in the study or initiation of study procedures

Exclusion Criteria:

  • Has a known hypersensitivity to any of the investigational drug or vehicle or standard of care gel components
  • Has been exposed to any investigational agent within 30 days of entry into the study
  • A female who is pregnant or nursing
  • Has active malignant disease of any kind except for basal cell carcinoma (of the skin). A subject, who has had a malignant disease in the past, was treated and is currently disease-free, may be considered for study entry.
  • Has a hemoglobin of less than 8.5 gm/dL.
  • Transaminase levels greater than 3 × normal
  • Is receiving hemodialysis or chronic ambulatory peritoneal dialysis (CAPD) therapy
  • Has had prior radiation therapy to any part of the foot with the target ulcer under study
  • Use of systemic corticosteroids and immunosuppressants (within the 8 weeks prior to screening)
  • Has an ulcer primarily ischemic in etiology
  • Has sickle-cell anemia, Reynaud's, or peripheral vascular disease
  • Has received a biologic agent, growth factor, or skin equivalents (Regranex®, Apligraft, or Dermagraft), in the past 30 days
  • Has a target ulcer which is determined to be clinically infected and requires antimicrobials. Any antibiotic therapy must be completed or discontinued at Screening.
  • Has a Wagner Grade 3 or higher DFU, deep abscess, or gangrene
  • Has uncontrolled hypertension, in the opinion of the Investigator.
  • Any other finding, which in the opinion of the Investigator, may interfere with the assessment of the product or participation of the patient in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01849965


  Show 56 Study Locations
Sponsors and Collaborators
Integra LifeSciences Corporation
Integrium
Investigators
Layout table for investigator information
Study Director: Alan Dunton, MD Integra LifeSciences Corporation

Layout table for additonal information
Responsible Party: Integra LifeSciences Corporation
ClinicalTrials.gov Identifier: NCT01849965     History of Changes
Other Study ID Numbers: DSC127-2012-02
First Posted: May 9, 2013    Key Record Dates
Last Update Posted: December 12, 2017
Last Verified: December 2017

Keywords provided by Integra LifeSciences Corporation:
diabetic foot ulcers
Wagner Grade 1 or 2 ulcers

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetic Foot
Foot Ulcer
Ulcer
Pathologic Processes
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Foot Diseases